Stanford Health Policy is a joint effort of the Freeman Spogli Institute for International Studies and the Stanford School of Medicine
Publications
Publications
Featured Publications
American Journal of Health Economics
Sherri Rose
Health Affairs
By Tara Templin
Publications
Filter:
Filter results Close
The Americas
Caribbean
Antigua & Barbuda
Bahamas
Barbados
Cuba
Dominica
Dominican Republic
Grenada
Haiti
Jamaica
St. Kitts & Nevis
St. Lucia
St. Vincent & the Grenadines
Trinidad & Tobago
Central America
Belize
Costa Rica
El Salvador
Guatemala
Honduras
Nicaragua
Panama
North America
Canada
Mexico
United States
South America
Argentina
Bolivia
Brazil
Chile
Colombia
Ecuador
Guyana
Paraguay
Peru
Suriname
Uruguay
Venezuela
Asia-Pacific
Northeast Asia
China
Japan
Mongolia
North Korea
South Korea
Taiwan
Oceania
Australia
Fiji
Kiribati
Marshall Islands
Micronesia
Nauru
New Zealand
Palau
Papua New Guinea
Samoa
Solomon Islands
Tonga
Tuvalu
Vanuatu
South Asia
Afghanistan
Bangladesh
Bhutan
India
Maldives
Nepal
Pakistan
Sri Lanka
Southeast Asia
Brunei
Burma
Cambodia
East Timor
Indonesia
Laos
Malaysia
Philippines
Singapore
Thailand
Vietnam
Europe
Eastern Europe
Albania
Bosnia & Herzegovina
Bulgaria
Croatia
Kosovo
Macedonia
Montenegro
Romania
Serbia
Central Europe
Austria
Czech Republic
Germany
Hungary
Liechtenstein
Poland
Slovakia
Slovenia
Switzerland
Iberian Peninsula
Andorra
Portugal
Spain
Scandinavia and Baltic Rim
Denmark
Estonia
Finland
Latvia
Lithuania
Norway
Sweden
Western Europe
Belgium
Cyprus
France
Greece
Iceland
Ireland
Italy
Luxembourg
Malta
Monaco
Netherlands
San Marino
United Kingdom
Vatican City
Middle East and North Africa
Algeria
Bahrain
Egypt
Iran
Iraq
Israel
Jordan
Kuwait
Lebanon
Libya
Morocco
Oman
Qatar
Saudi Arabia
Syria
Tunisia
Turkey
United Arab Emirates
Yemen
Russia and Eurasia
Armenia
Azerbaijan
Belarus
Georgia
Kazakhstan
Kyrgyzstan
Moldova
Russia
Tajikistan
Turkmenistan
Ukraine
Uzbekistan
Sub-Saharan Africa
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African Republic
Chad
Comoros
D.R. Congo
Congo
Côte d'Ivoire
Djibouti
Equatorial Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mauritius
Mozambique
Namibia
Niger
Nigeria
Rwanda
Säo Tomé & Príncipe
Senegal
Seychelles
Sierra Leone
Somalia
South Africa
South Sudan
Sudan
Swaziland
Tanzania
Togo
Uganda
Zambia
Zimbabwe
Governance
Corruption
Democracy
Democracy promotion
Disaster response
Staff
Elections
European Union
Health care institutions
Health Care Reform
Homeland Security
Human Rights
Information Technology
Intelligence
Institutions and Organizations
International Law
Kyoto Protocol
Media
Military
NATO
Negotiation
Peacekeeping
Nuclear policy
Policy Analysis
Rule of Law
State-building
World Bank
World Trade Organization
International Relations
Agricultural trade
Borders
Business
Diplomacy
Foreign Aid
Foreign Policy
Globalization
HIV/AIDS
Investment
Migration and Citizenship
Protectionism
Trade
Health and Medicine
Children's health
Early Childhood Development
Health
Vision Care
Comparative effectiveness research
Diabetes
Health policy
Hypertension
Hunger
Disease
Global Health
Health and the Environment
Health Care
Health Outcomes
Nutrition
Obesity
Population health
Public Health
Smoking
International Development
In the Classroom
Technology
Agriculture policy
Cleantech
Economic Affairs
Education
Entrepreneurship
Food Markets
Food Security
Innovation
Poverty
Science and Technology
Security
Arms Control
Arms Smuggling
Biosecurity
Bioterrorism
Civil Wars
Conflict
Crime
Cybersecurity
Drug trafficking
Kidnapping
Missiles
Nuclear Risk
Nuclear Safety
Terrorism
Torture convention
Violence
Energy
Biofuels
Cap and Trade
Coal
Electricity
Energy and Climate Policy
Energy Infrastructure
Energy Services
Fossil Fuels
Natural gas
Nuclear Energy
Natural gas
Renewable Resources
Oil
Water
Environment
Palm Oil
Agriculture
Aquaculture
Climate
Climate change
Deforestation
Fisheries
Natural Resources
Sustainable development
Society
Aging
Inclusion and Exclusion
Inequality
Migration
Migration and Citizenship
Race
SAI
Culture
Demographics
Discrimination
Ethnicity
Gender
History
Islam
Religion
Abstracts
Blogs
Books
Book Chapters
Case Studies
Conference Memos
Commentary
Dissertations
Journal Articles
News
Policy Briefs
Q&As
Testimonies
White Papers
Reports
Working Papers
Annual Reports
Brochures
Newsletters
Mark Holodniy
Journal Articles
Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States
Cora L. Bernard, Margaret L. Brandeau, Keith Humphreys, Eran Bendavid, Mark Holodniy, Christopher Weyant, Douglas K. Owens, Jeremy Goldhaber-Fiebert
Annals of Internal Medicine,
2016
July 5, 2016
Background: The total population health benefits and costs of HIV preexposure prophylaxis (PrEP) for people who inject drugs (PWID) in the United States are unclear.
Objective: To evaluate the cost-effectiveness and optimal delivery conditions of PrEP for PWID.
Design: Empirically calibrated dynamic compartmental model.
Data Sources: Published literature and expert opinion.
Target Population: Adult U.S. PWID.
Time Horizon: 20 years and lifetime.
Journal Articles
Risk of Cardiovascular Events Associated With Current Exposure to HIV Antiretroviral Therapies in a US Veteran Population
Manisha Desai, Vilija Joyce, Eran Bendavid, Richard A. Olshen, Mark A. Hlatky, Adam Chow, Mark Holodniy, Paul Barnett, Douglas K. Owens
Clinical Infectious Diseases,
2015
August 1, 2015
Background. To characterize the association of antiretroviral drug combinations on risk of cardiovascular events.
Journal Articles
Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users
Cipriano, L.E., Zaric, G.S., Mark Holodniy, Eran Bendavid, Douglas K. Owens, Margaret L. Brandeau
PLoS One,
2012
December 31, 2012
Journal Articles
New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis
Shan Liu, Lauren E. Cipriano, Mark Holodniy, Douglas K. Owens, Jeremy Goldhaber-Fiebert
Annals of Internal Medicine,
2012
February 21, 2012
Background: Chronic hepatitis C virus is difficult to treat and affects approximately 3 million Americans. Protease inhibitors increase the effectiveness of standard therapy, but they are costly. A genetic assay may identify patients most likely to benefit from this treatment advance.
Objective: To assess the cost-effectiveness of new protease inhibitors and an interleukin (IL)–28B genotyping assay for treating chronic hepatitis C virus.
Journal Articles
Determinants of the cost of health services used by veterans with HIV
Barnett PG, Chow A, Vilija Joyce, Bayoumi AM, Griffin SC, Nosyk B, Mark Holodniy, Brown ST, Sculpher M, Anis AH, Douglas K. Owens
Medical Care,
2011
December 31, 2011
BACKGROUND:
The effect of adherence, treatment failure, and comorbidities on the cost of HIV care is not well understood.
OBJECTIVE:
To characterize the cost of HIV care including combination antiretroviral treatment (ART).
RESEARCH DESIGN:
Observational study of administrative data.
SUBJECTS:
Total 1896 randomly selected HIV-infected patients and 288 trial participants with multidrug-resistant HIV seen at the US Veterans Health Administration (VHA).
MEASURES:
Comorbidities, cost, pharmacy, and laboratory data.
Journal Articles
One-year outcomes of community-acquired and health care-associated pneumonia in the Veterans Affairs Health Care System
Hsu JL, Siroka AM, Mark W. Smith, Mark Holodniy, Meduri GU
International Journal of Infectious Disease,
2011
December 31, 2011
Abstract
BACKGROUND:
While studies have demonstrated higher medium-term mortality for community-acquired pneumonia (CAP), mortality and costs have not been characterized for healthcare-associated pneumonia (HCAP) over a 1-year period.
Journal Articles
Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-related Quality of Life in Patients with Advanced HIV
Vilija Joyce, Paul G. Barnett, Adam Chow, Ahmed M. Bayoumi, Susan C. Griffin, Huiying Sun, Mark Holodniy, Sheldon T. Brown, Tassos C. Kyriakides, D. William Cameron, Mike Youle, Mark Sculpher, Aslam H. Anis, Douglas K. Owens
Medical Decision Making,
2011
March 7, 2011
Background. The effect of antiretroviral therapy (ART) interruption or intensification on health-related quality of life (HRQoL) in advanced HIV patients is unknown.
Objective. To assess the impact of temporary treatment interruption and intensification of ART on HRQoL.
Design. A 2 x 2 factorial open label randomized controlled trial.
Setting. Hospitals in the United States, Canada, and the United Kingdom.
Journal Articles
Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-drug Resistant HIV Infection from the OPTIMA trial
Mark Holodniy, Sheldon T. Brown, D. William Cameron, Tassos C. Kyriakides, Brian Angus, Abdel Babiker Abdel Babiker, Joel Singer, Douglas K. Owens, Aslam Anis, Ruth Goodall, Fleur Hudson, Mirek Piaseczny, John Russo, Martin Schechter, Lawrence Deyton, Janet Darbyshire
PLoS ONE,
2011
March 1, 2011
Background Guidance is needed on best medical management for advanced HIV disease with multidrug resistance (MDR) and limited retreatment options. We assessed two novel antiretroviral (ARV) treatment approaches in this setting.
Journal Articles
Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events.
Anis AH, Nosyk B, Sun HSun H, Guh DPGuh DP, Bansback NBansback N, Li X, Paul G. Barnett, Vilija Joyce, Swanson KM, Kyriakides TC, Mark Holodniy, Cameron DW, Brown ST, OPTIMA TEAM
JAIDS,
2009
December 31, 2009
Journal Articles
The Concurrent Validity and Responsiveness of the Health Utilities Index (HUI 3) Among Patients with Advanced HIV/AIDS
Nosyk B, Sun H, Bansback N, Guh DP, Li X, Paul G. Barnett, Bayoumi A, Griffin S, Vilija Joyce, Mark Holodniy, Douglas Owens, Anis AH
Quality of Life Research,
2009
June 27, 2009
Objectives To assess the concurrent validity and responsiveness of the Health Utility Index 3 (HUI3) in patients with advanced HIV/AIDS, and to determine the responsiveness of this measure, the MOS-HIV and EQ-5D to HIV-related clinical events.
Journal Articles
Health-related Quality of Life in a Randomized Trial of Antiretroviral Therapy for Advanced HIV Disease
Vilija Joyce, Paul G. Barnett, Bayoumi AM, Griffin SC, Kyriakides TC, Wei Yu, Vandana Sundaram, Mark Holodniy, Brown ST, Cameron W, Youle M, Sculpher M, Anis AH, Douglas Owens
Journal of Acquired Immune Deficiency Syndromes,
2009
January 1, 2009
OBJECTIVE: To assess and compare alternative approaches of measuring preference-based health-related quality of life (HRQoL) in treatment-experienced HIV patients and evaluate their association with health status and clinical variables. DESIGN: Cross-sectional study.
SETTING: Twenty-eight Veterans Affairs hospitals in the United States, 13 hospitals in Canada, and 8 hospitals in the United Kingdom.
PATIENTS: Three hundred sixty-eight treatment-experienced HIV-infected patients enrolled in the Options in Management with Antiretrovirals randomized trial.
Journal Articles
Frequency of HIV Screening in the Veterans Health Administrations: Implications for Early Diagnosis of HIV Infection
Valdiserri R, Rodriguez F, Mark Holodniy
AIDS Education and Prevention,
2008
December 31, 2008
We evaluated the frequency of HIV testing across the Department of Veterans Affairs (VA), the largest provider of HIV care in the United States. An electronic survey was used to determine the volume and location of HIV screening, confirmatory testing, rapid testing and laboratory consent policies in VA medical centers between October 1, 2005, and September 30, 2006. One hundred thirty-five VA laboratories reported that 112,033 HIV screening tests were performed (81% outpatients vs. 19% inpatients, p<.0001). Overall HIV prevalence was 1.49% (1.62% in inpatients vs.
Journal Articles
Cost Effectiveness of HIV Screening in the Elderly
Gillian D. Sanders, Bayoumi AM, Mark Holodniy, Douglas K. Owens
Ann Intern Med,
2008
December 31, 2008
Although HIV infection is more prevalent in people younger than age 45 years, a substantial number of infections occur in older persons. Recent guidelines recommend HIV screening in patients age 13 to 64 years. The cost-effectiveness of HIV screening in patients age 55 to 75 years is uncertain. OBJECTIVE: To examine the costs and benefits of HIV screening in patients age 55 to 75 years. DESIGN: Markov model. DATA SOURCES: Derived from the literature. TARGET POPULATION: Patients age 55 to 75 years with unknown HIV status. TIME HORIZON: Lifetime. PERSPECTIVE: Societal.
Journal Articles
The Prevalence of HIV-1 Infection Amoung Inpatients and Outpatients in Department of Veterans Affairs Health Care Systems: Implications for Screening Programs for HIV
Douglas K. Owens, Vandana Sundaram, Lazzeroni LC, Douglass LR, Gillian D. Sanders, Taylor K, VanGroningen R, Shadle VM, McWhorter VCMcWhorter VC, Agoncillo TAgoncillo T, Haren N, Nyland J, Tempio P, Khayr W, Dietzen D, Jensen P, Simberkoff MS, Bozzette SA, Mark Holodniy
Am J Public Health,
2007
December 31, 2007
OBJECTIVES: We sought to determine the prevalence of HIV in both inpatient and outpatient settings in 6 Department of Veterans Affairs (VA) health care sites. METHODS: We collected demographic data and data on comorbid conditions and then conducted blinded, anonymous HIV testing. We conducted a multivariate analysis to determine predictors of HIV infection. RESULTS: We tested 4500 outpatient blood specimens and 4205 inpatient blood specimens; 326 (3.7%) patients tested positive for HIV. Inpatient HIV prevalence ranged from 1.2% to 6.9%; outpatient HIV prevalence ranged from 0.9% to 8.9%.
Journal Articles
A Systematic Review of Cost-Utility Analyses in HIV/AIDS
Hornberger J, Mark Holodniy, Robertus K, Winnike M, Gibson M, Verhulst E
Medical Decision Making,
2007
December 31, 2007
OBJECTIVES: To determine whether gaps exist in published cost-utility analyses as measured by their coverage of topics addressed in current HIV guidelines from the Department of Health and Human Services (DHHS).
DESIGN: A systematic review of US-based cost-effectiveness analyses of HIV/AIDS prevention and management strategies, based on original, published research.
Journal Articles
Relationship between Antiretroviral Prescribing Patterns and Treatment Guidelines in Treatment-Naive, HIV-1 Infected U.S. Veterans
Mark Holodniy, Hornberg J, Rapoport D, Robertus K, MaCurdy TE, Lopez J, Volberding P, Deyton L
JAIDS,
2007
December 31, 2007
To analyze temporal patterns of antiretroviral (ARV) prescribing practices relative to nationally defined guidelines in treatment-naive patients with HIV-1 infection. DESIGN: Retrospective cohort study. METHODS: We evaluated ARV prescribing patterns among ARV treatment-naive veterans who were receiving care within the US Department of Veterans Affairs (VA) from 1992 through 2004 in comparison to evolving adult HIV-1 treatment guidelines. RESULTS: A total of 15,934 patients initiated ARV treatment.